Genitourinary Cancers Symposium

Genitourinary Cancers Symposium
The 2018 Genitourinary (GU) Cancers Symposium, hosted by the American Society of Clinical Oncology in San Francisco, California, on February 8-10, brings together physicians and other members of the cancer care and research community who diagnose, treat, and study GU malignancies to discuss new research and its clinical application. Sign up for our emails on our registration page to get the latest news and check back here during the conference for more updates
May 27, 2018
Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research.
May 04, 2018
Funding is the biggest challenge scientists and clinical investigators face when trying to find successful therapies to treat advanced bladder cancer, explained Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine.
April 29, 2018
New therapies and imaging modalities have helped providers treat patients who have prostate cancer earlier, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
 
April 19, 2018
Having numerous therapies to treat prostate cancer can actually be a bad thing—it makes it difficult to design clinical trials for new therapies coming into the space, explained Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
April 03, 2018
Physicians using molecular therapies need to be educated on where the therapies are best used during treatment, and patients need to understand that the radiation is safe for those around them, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
March 28, 2018
mTOR is a very promising pathway because it’s so central in growth,  migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego. 
February 28, 2018
Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego. 
February 14, 2018
There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
February 11, 2018
In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.
February 10, 2018
The addition of docetaxel to first-line long-term hormone therapy in patients with prostate cancer is associated with improved quality of life (QoL) benefits and cost effectiveness, according to study results presented at the 2018 Genitourinary Cancers Symposium.
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.